Linzess (linaclotide) is generally considered the stronger of the two medications for chronic constipation. In clinical trials, Linzess produced a larger increase in weekly bowel movements over placebo, and it carries a stronger recommendation from the American Gastroenterological Association. That said, “stronger” doesn’t always mean “better for you,” because each drug works differently and causes different side effects.
How They Compare in Clinical Trials
Both Linzess and Amitiza (lubiprostone) have been tested in large, placebo-controlled trials for chronic idiopathic constipation (CIC). The most useful measure is the change in spontaneous bowel movements (SBMs) per week compared to placebo.
In U.S. and Canadian trials, Linzess at its standard constipation dose increased weekly bowel movements by about 2.6 to 3.6 more than baseline over 12 weeks, compared to roughly 1.1 to 1.6 for placebo. That translates to a net gain of roughly 1.5 to 2 extra bowel movements per week beyond what a sugar pill provides.
Amitiza trials measured things slightly differently, often reporting total weekly SBM frequency rather than change from baseline. In those studies, patients on Amitiza averaged about 5.7 to 5.9 bowel movements per week at week one, versus 3.5 to 4.0 for placebo. The net advantage is in a similar ballpark, around 1.5 to 2 extra movements per week, though direct cross-trial comparisons are imperfect because the patient populations and study designs differ.
A systematic review and meta-analysis published in BMC Gastroenterology compiled data from trials of both drugs, and the overall pattern favors Linzess for producing more consistent, sustained improvements in bowel frequency over longer treatment periods.
What the Guidelines Say
The joint clinical practice guideline from the American Gastroenterological Association and the American College of Gastroenterology draws a clear distinction between the two. Linzess receives a strong recommendation based on moderate-certainty evidence for adults with CIC who haven’t responded to over-the-counter options. Amitiza receives only a conditional recommendation backed by low-certainty evidence.
That difference matters. A strong recommendation means the guideline panel was confident that the benefits clearly outweigh the risks for most patients. A conditional recommendation means the balance is closer, and the decision depends more on individual circumstances and preferences.
How Each Drug Works
Despite treating the same conditions, these medications use entirely different mechanisms. Amitiza is a prostaglandin-based compound that activates specific chloride channels on the lining of the intestine. When those channels open, chloride ions flow into the gut, pulling water along with them. The extra fluid softens stool and stimulates movement through the bowel.
Linzess works through a different receptor system altogether. It activates a receptor on intestinal cells that triggers a cascade increasing fluid secretion into the gut, similar to the body’s natural process for keeping the intestinal lining hydrated. This pathway also helps maintain the intestinal barrier and, importantly, reduces visceral pain signaling. That pain-reducing effect is one reason Linzess tends to be favored for irritable bowel syndrome with constipation (IBS-C), where abdominal pain is a core symptom, not just a side issue.
Side Effects Are the Real Differentiator
The main side effect of Linzess is diarrhea. Among patients who stopped Linzess within the first three months, diarrhea was the reason 30.5% of the time. It remained the dominant complaint even among those who stopped later, accounting for about 33% of discontinuations between months three and twelve. When researchers looked specifically at patients who quit due to intolerance, diarrhea drove 53% of early stops and 65% of late ones.
Amitiza’s signature side effect is nausea. Among early discontinuations due to intolerance, nausea was responsible 41% of the time, followed by abdominal pain at 27%. Diarrhea was a relatively minor issue with Amitiza, causing only about 12% of early intolerance-related stops. Nausea persisted as the top complaint even in later months, accounting for half of all late discontinuations due to intolerance.
This means your choice often comes down to which side effect you’re more willing to tolerate. If you’re prone to nausea or have a sensitive stomach, Linzess may be the better fit. If loose stools are already an issue for you or would be particularly disruptive, Amitiza might be more manageable despite its lower guideline ranking.
Approved Uses and Dosing
Linzess has a broader approval profile. It’s FDA-approved for CIC in adults, IBS-C in adults and children 7 and older, and functional constipation in children 6 and older. For adult CIC, the standard dose is 145 mcg once daily, with a lower 72 mcg option for those who need a gentler start. For IBS-C in adults, the dose is higher at 290 mcg once daily.
Amitiza is approved for CIC, IBS-C (specifically in women 18 and older), and opioid-induced constipation in adults with chronic non-cancer pain. That last indication is notable: if your constipation is caused by opioid medications, Amitiza is one of the few prescription options specifically approved for that situation, and Linzess is not.
Choosing Between Them
If you’re comparing these two purely on constipation relief, Linzess has the stronger evidence base and the higher guideline recommendation. It also offers the added benefit of reducing abdominal pain, which matters if cramping and discomfort are part of your daily experience.
Amitiza still has a clear role, though. It’s a reasonable option if you’ve tried Linzess and couldn’t tolerate the diarrhea, if your constipation is opioid-induced, or if nausea is less of a concern for you than loose stools. Some patients also respond better to one mechanism than the other for reasons that aren’t fully predictable, so switching between them is common in practice.
Both medications are taken once or twice daily (Linzess once, Amitiza typically twice), both are available as capsules, and both work best when taken on an empty stomach or with food as directed. Cost and insurance coverage vary significantly and can sometimes be the deciding factor regardless of which drug is technically more potent.